TEAM 3 (Director: Pr Jean-Pierre Cazenave)
The work of this team focuses primarily on clinical haemostasis and transfusion research. The aim is to develop and apply to haemorrhagic and thrombotic diseases and to transfusion research the progress in our understanding of the molecular and cellular mechanisms involved in haemostasis and thrombosis and investigated by teams 1 and 2.
The location of this group within a blood transfusion centre has led to the development of an important pole of applied research concerning the improvement of transfusion techniques and to the design of experimental haemorrhagic models to test transfusion therapy in the rat and the mouse, in view of a clinical application in haemorrhagic diseases. This team lies at the interface between the University Hospital of Strasbourg where the patients are seen and the fundamental research of the other groups of the unit.
The principal findings concern the characterization of haemorrhagic and thrombotic diseases, with a particular emphasis on soluble GPV as a new marker of thrombosis. In transfusion medicine, the major results relate to a procedure for the inactivation of platelet concentrates using a psoralen, amotosalen, tested in two therapeutic trials in man.
The projects of this team will focus on the clinical evaluation of soluble GPV as a new marker of thrombosis and on the study of thrombin generation (Thrombogram®) and GPV release in animal models and man, in different thrombotic situations and during antithrombotic treatment with antiplatelet agents or anticoagulants. Another important aspect will be the improvement of cellular transfusion products using an experimental approach in haemorrhagic models in the rat and also clinical trials. One major recent development concerns the viral and bacterial inactivation of platelet concentrates with psoralen derivatives.
